Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2012 on February 13

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (the "Company") today announced that President and Chief Executive Officer, Igor Gonda, Ph.D., will present at the 14^th Annual BIO CEO & Investor Conference 2012 on Monday, February 13, 2012, at 2:30 p.m. ET. The event will be held at the Waldorf-Astoria Hotel in New York, New York.

Interested parties can access a live audio webcast and slide presentation at www.aradigm.com. An archived presentation will be available on the Company's Web site for 14 days.

About Aradigm

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

More information about Aradigm can be found at www.aradigm.com.

Aradigm and the Aradigm Logo are registered trademarks of Aradigm Corporation.

Contacts

Aradigm Corporation
Nancy Pecota, 510-265-8800
Chief Financial Officer

Recent Stories from Aradigm Corporation

Aradigm Announces First Quarter 2012 Financial Results

May 11, 2012

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation announces first quarter 2012 financial results. more »
Aradigm Announces Fourth Quarter 2011 and Full Year Financial Results

March 27, 2012

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm announces fourth quarter 2011 and full year 2011 financial results. more »
Aradigm Receives U.S. FDA Clearance for Phase 3 Clinical Trial of Pulmaquin™ in Patients with Non-Cystic Fibrosis Bronchiectasis

March 12, 2012

HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm announces that its Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin in bronchiectasis has been cleared b... more »